Dominican Republic Parenteral and Enteral Nutrition Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Dominican Republic Parenteral and Enteral Nutrition Market Size

• The Dominican Republic Parenteral & Enteral Nutrition Market size was valued at USD 68.72 million in 2024 and is expected to reach USD 118.05 million by 2032, at a CAGR of 7.1% during the forecast period
• The parenteral and enteral nutrition market is a vital and steadily growing sector, driven by increasing awareness of clinical nutrition's role in patient recovery, chronic disease management, and overall health outcomes. With an emphasis on providing essential nutrients to individuals unable to meet their dietary needs through normal oral intake
• The market includes a broad spectrum of nutritional formulas administered either intravenously (parenteral) or through the gastrointestinal tract (enteral). These solutions are critical for patients suffering from conditions such as cancer, gastrointestinal disorders, neurological impairments, and those in intensive care units

Dominican Republic Parenteral and Enteral Nutrition Market Analysis

• According to the National Library of Medicine, home enteral nutrition is primarily for patients in whom there is a reduction in oral intake below the amount needed to maintain nutrition or hydration (i.e., oral failure), whereas home parenteral nutrition is used for patients when oral-enteral nutrition is temporarily or permanently impossible or absorption insufficient to maintain nutrition or hydration (i.e., intestinal failure)
• Technological advancements in nutrient formulation, delivery systems, and safety protocols have significantly enhanced the efficacy and precision of nutritional therapies. In the Dominican Republic, rising healthcare infrastructure, a growing aging population, and an increased prevalence of lifestyle-related diseases contribute to the expanding demand for both parenteral and enteral nutrition products. Furthermore, the integration of these nutritional therapies into postoperative care, long-term care, and home healthcare settings supports market growth
• Enteral Nutrition (EN) dominated the Dominican Republic parenteral & enteral nutrition market with 64.10% revenue share in 2024, driven by its widespread adoption as the preferred method for long-term nutritional support. Rising prevalence of chronic illnesses such as cancer, gastrointestinal disorders, and neurological conditions has increased demand for cost-effective and clinically efficient nutrition solutions. In addition, advancements in disease-specific formulations, growing hospital usage, and the shift toward home healthcare have strengthened EN’s position as the leading segment over parenteral nutrition in the global market

Report Scope and Dominican Republic Parenteral and Enteral Nutrition Market Segmentation 

Dominican Republic Parenteral & Enteral Nutrition Market Trends

“Advancements in Clinical Nutrition, Home-Based Care, and Disease-Specific Formulations”

• The Dominican Republic Parenteral & Enteral Nutrition (PEN) market is undergoing a major transformation with rising emphasis on clinical nutrition for critically ill patients, as well as personalized formulations tailored to disease-specific needs
• Hospitals are reformulating traditional nutritional protocols by incorporating ready-to-use (RTU) parenteral bags, specialized enteral blends, and immune-modulating formulas designed for oncology, gastrointestinal disorders, and critical care
• For instance, regional distributors have expanded their portfolios with high-protein enteral formulas enriched with probiotics, prebiotics, and omega-3 fatty acids to address malnutrition and improve recovery outcomes
• This trend reflects growing awareness of the role of nutrition in patient recovery, prevention of complications, and enhanced quality of life, positioning PEN products as a critical component of modern healthcare delivery in the Dominican Republic

Dominican Republic Parenteral & Enteral Nutrition Market Dynamics

Driver

“Increasing Demand for Clinical Nutrition in Hospitals and Homecare”

• The rise in chronic diseases such as cancer, Crohn’s disease, and gastrointestinal disorders is expanding the adoption of both parenteral and enteral nutrition therapies
• Home enteral nutrition (HEN) is gaining traction, supported by patients seeking cost-effective, long-term nutritional care outside hospital settings
• Ready-to-use PN solutions and digitally integrated feeding pumps are reducing risks of contamination and improving patient safety, enhancing adoption across hospitals and homecare facilities
• In 2024, several regional hospitals partnered with global nutrition brands to expand access to pediatric and neonatal formulations, highlighting the rising focus on vulnerable patient groups.
• Such collaborations underscore how healthcare providers and manufacturers are advancing clinical nutrition protocols to address diverse patient needs, ultimately driving sustained growth in the Dominican Republic PEN market

Restraint/Challenge

“High Costs and Limited Local Manufacturing Capacity”

• The substantial cost of sourcing specialized nutrition products, compounded PN solutions, and disease-targeted enteral blends poses a challenge for affordability, particularly in middle- and low-income patient groups
• These costs include reliance on imported formulations, limited local production capacity, stringent regulatory compliance, and high distribution expenses across rural regions
• In addition, the shortage of trained nutrition specialists and compounding pharmacists restricts the safe administration of PN and EN therapies in some hospitals
• In 2023, reports from regional healthcare associations highlighted that the cost of introducing advanced PN formulations goes beyond product sourcing—covering investments in compounding facilities, cold-chain logistics, regulatory approvals, and clinical training
• Smaller healthcare providers and distributors often lack the financial capacity or infrastructure to manage these challenges, delaying the broader adoption of advanced PEN solutions
• This financial and operational barrier slows innovation, limits accessibility, and concentrates market opportunities among a few multinational suppliers dominating the Dominican Republic PEN landscape

Dominican Republic Parenteral & Enteral Nutrition Market Scope

The market is segmented on the basis of product type, age group, care type and distribution channel.

• By Product Type

On the basis of product type, the parenteral & enteral nutrition market is segmented into Eternal Nutrition (EN) and Parenteral Nutrition (PN). In 2025 Eternal Nutrition (EN) segment is expected to dominate the market with a market share of 64.61% and it is anticipated to show the fastest growth during the forecast period with a CAGR of 7.9%. This dominance is attributed to its lower risk of complications compared to parenteral methods, cost-effectiveness, and growing acceptance of gastrointestinal-based feeding. EN is widely preferred in clinical settings as well as homecare, as it supports natural digestive processes while reducing infection risks. Its efficiency in providing essential nutrients while minimizing healthcare costs further strengthens its leading position.

• By Age Group

On the basis of age group, the parenteral & enteral nutrition market is segmented into adult, geriatric, and pediatric. In 2025 the adult segment is expected to dominate the market with a market share of 58.13% and it is anticipated to show the fastest growth during the forecast period with a CAGR of 7.4%. as due to This trend is primarily driven by the higher prevalence of chronic diseases, such as diabetes and cancer, which often require nutritional support during treatment. In addition, rising surgical interventions and hospital admissions among adults further fuel the demand for both enteral and parenteral nutrition. With an expanding adult patient base, this segment continues to anchor overall market growth.

• By Care Type

On the basis of Care Type, the parenteral & enteral nutrition market is segmented into Acute Care, Post Acute, Preoperative Care, Urgent Care, General Care, and others. In 2025, the acute care segment is expected to dominate the market with a market share of 39.08% and it is anticipated to show the fastest growth during the forecast period with a CAGR of 7.8%. This is largely due to the rising incidence of critical illnesses, trauma cases, and intensive care admissions that demand immediate nutritional support. Patients in intensive or emergency settings often require carefully monitored feeding methods to stabilize health outcomes. The urgent need for rapid recovery and prevention of complications in high-risk patients drives strong adoption of nutritional therapies in acute care environments.

• By Distribution Channel

On the basis of Distribution Channel, the parenteral & enteral nutrition market is segmented into direct trader, retail sales, and others. In 2025, the Direct Trader segment is expected to dominate the market with a market share of 61.20% and it is anticipated to show the fastest growth during the forecast period with a CAGR of 7.5%, due to Strong procurement partnerships with hospitals, clinics, and healthcare institutions contribute to its dominance. Direct traders also offer competitive pricing structures through bulk purchases, which appeal to large-scale healthcare buyers. In addition, efficient supply chain management ensures timely and reliable delivery of clinical nutrition products, reducing the risk of shortages. These advantages make direct trading the preferred channel for institutional buyers.

Dominican Republic Parenteral & Enteral Nutrition Market Regional Analysis

• Dominican Republic is growing with a CAGR of 7.1% during the forecast period due to rising hospital admissions, increasing chronic disease prevalence, expanding healthcare infrastructure, and growing adoption of home-based nutritional care solutions across diverse patient demographics and treatment settings.
• Rising awareness of nutritional needs, technological advancements, and improved healthcare infrastructure are contributing to the growth of the clinical nutrition market in the country
• These factors are likely influencing the adoption of enteral and parenteral nutrition therapies in the Dominican Republic.

Dominican Republic Parenteral & Enteral Nutrition Market Share

The Dominican Republic Parenteral & Enteral Nutrition industry is primarily led by well-established companies, including

• Fresenius Kabi AG (Germany)
• Nestlé Health Science (Switzerland)
• Abbott Laboratories (Abbott) (U.S.)
• B. Braun SE (Germany)
• Baxter International Inc. (U.S.)
• Bayer AG (Germany)
• Nutricia (Netherlands)
• Grifols, S.A. (Spain)
• Mead Johnson Nutrition (U.S.)
• Cardinal Health, Inc. (U.S.)
• Carbery Group (Ireland), Macrotech (China)
• Botanic Supplements, LLC (U.S.)
• Grupo Hospifar (Dominican Republic)
• B&D Nutritional Ingredients (U.S.)
• AAK AB (Sweden)
• Otsuka Holdings Co., Ltd. (Japan)
• Balaxi Pharmaceuticals Limited (India)

Latest Developments in Dominican Republic Parenteral & Enteral Nutrition Market

• In February 2025, Biogen and Stoke Therapeutics have partnered to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome. This investigational antisense oligonucleotide targets the SCN1A gene to reduce seizures and improve cognition. A Phase 3 study begins in 2025, with regulatory filings expected in 2027. Stoke retains U.S. rights, while Biogen handles global commercialization
• In March 2025, Biogen will establish its new global headquarters at Kendall Common in Cambridge, Massachusetts, as part of a multi-year real estate consolidation. The state-of-the-art facility, set to open in 2028, will foster collaboration, innovation, and sustainability while housing Biogen’s research, development, and commercial teams alongside the Biogen CoLab for life sciences education
• In March 2025, Ionis Pharmaceuticals, Inc. announced that Wainzua (Eplontersen) has been approved by the European Medicines Agency (EMA) for the treatment of hereditary transthyretin amyloidosis (hATTR). This antisense therapy targets the underlying cause of the disease, offering a new therapeutic option for patients suffering from this rare, life-threatening condition
• In February 2024, Pfizer Inc. and UT Southwestern Medical Center have partnered to develop advanced RNA delivery technologies for genetic medicine. This collaboration integrates UTSW’s expertise in Lipid Nanoparticle (LNP) delivery systems with Pfizer’s RNA innovation to enhance RNA-based therapies. The research aims to expand gene editing applications, improve targeted delivery, and accelerate the development of next-generation genetic medicines
• In January 2022, Pfizer Inc. has partnered with Acuitas Therapeutics to expand Lipid Nanoparticle (LNP) delivery technology for mRNA-based vaccines and therapeutics. This agreement allows Pfizer to license Acuitas’ LNP technology for up to 10 targets, strengthening its mRNA strategy. The collaboration enhances vaccine development and enables next-generation genetic medicines, building on the success of COMIRNATY, the Pfizer-BioNTech COVID-19 vaccine

SKU-74743